This analysis indicates that in individuals with type 2 diabetes and high cardiovascular risk, tirzepatide may effectively mitigate the decline in eGFR and reduce UACR more effectively than insulin glargine
The medication is indicated for adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia
At one year, exposure was associated with a lower relative risk of lupus nephritis (RR 0.59, 95% CI 0.400.86), and lupus flare, all-cause mortality, acute myocardial infarction and hospitalisation were observed less frequently in the exposed group
KadowakiTIsendahlJKhalidULeeSYNishidaTOgawaWet alSemaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Group averages aren't a guarantee for any one person
Chelation therapy detoxifies heavy metals to enhance overall health, while peptide therapy promotes cellular repair for anti-aging effects